Skip to content
drillr.ai
Sign up

688180.SH

Shanghai Junshi Biosciences Co., Ltd.

SSE · Healthcare · Biotechnology · CN

Also listed · 01877.HK →
CNY 30.32
+2.09%
Ask drillr

  • Oct 29, 2026, 10:30 UTC

    Junshi Biosciences announced that the first patient was dosed in a Phase III trial of JS207 combined with JS007 as first-line treatment for advanced hepatocellular carcinoma.

    Source:

  • Oct 29, 2026, 10:29 UTC

    Junshi Biosciences reported revenue of 2.513 billion yuan for the first three quarters of 2026, up 39.18% year over year, and a net loss of 149 million yuan.

    Source:

  • Oct 29, 2026, 10:29 UTC

    Junshi Biosciences reported third-quarter 2026 revenue of 817 million yuan, up 28.19% year over year, and a net loss of 171 million yuan.

    Source:

  • Oct 28, 2026, 10:33 UTC

    China’s National Medical Products Administration accepted Junshi Biosciences’ application for a new first-line indication of subcutaneous toripalimab combined with disitamab vedotin for HER2-expressing locally advanced or metastatic urothelial carcinoma.

    Source:

  • Oct 23, 2026, 12:10 UTC

    Junshi Biosciences reported that the first patient has been dosed in its Phase III trial of JS203 combined with chemotherapy for relapsed or refractory diffuse large B-cell lymphoma.

    Source:

  • Sep 29, 2026, 07:07 UTC

    Junshi Biosciences, Haiyan County State-owned Capital Investment and Operation, and Haiyan Jiarui Zhanxin Equity Investment Partnership jointly established Jiaxing Yuanhe Chuangfu Equity Investment Partnership in Jiaxing with RMB 360 million in capital contributions.

    Source:

  • Sep 14, 2026, 10:00 UTC

    Shanghai Junshi Biosciences held an online investor briefing on its 2026 half-year results on September 14, 2026, with CEO Zou Jianjun, independent non-executive director Li Zhongxian, CFO Xu Baohong and board secretary Wang Zhengyu receiving investors.

    Source:

  • Sep 14, 2026, 05:17 UTC

    Junshi Biosciences announced at its 2026 interim results briefing that Phase III clinical trials for its drug candidates JS203 and JS207 are expected to start within 2026.

    Source:

  • Aug 31, 2026, 09:19 UTC

    Junshi Biosciences announced the cancellation of 6.3 million H shares repurchased between May 26 and June 4, 2026, at a price of HK$17.51 per share, reducing total issued shares to 327,888,000.

    Source:

  • Aug 26, 2026, 09:34 UTC

    Junshi Biosciences reported interim results for the six months ended June 2026, with revenue of RMB 1.696 billion, up 45% year-on-year, and a net profit of RMB 25.501 million, turning around from a loss of RMB 413 million in the same period last year.

    Source:

  • Aug 19, 2026, 10:49 UTC

    Shanghai Tanying Investment Partnership reduced its stake in Junshi Biosciences by 2% through block trades, completing its planned reduction period.

    Source: